12 research outputs found
Phishing websites detection using a novel multipurpose dataset and web technologies features
[EN] Phishing attacks are one of the most challenging social engineering cyberattacks due to the large amount of entities involved in online transactions and services. In these attacks, criminals deceive users to hijack their credentials or sensitive data through a login form which replicates the original website and submits the data to a malicious server. Many anti-phishing techniques have been developed in recent years, using different resource such as the URL and HTML code from legitimate index websites and phishing ones. These techniques have some limitations when predicting legitimate login websites, since, usually, no login forms are present in the legitimate class used for training the proposed model. Hence, in this work we present a methodology for phishing website detection in real scenarios, which uses URL, HTML, and web technology features. Since there is not any updated and multipurpose dataset for this task, we crafted the Phishing Index Login Websites Dataset (PILWD), an offline phishing dataset composed of 134,000 verified samples, that offers to researchers a wide variety of data to test and compare their approaches. Since approximately three-quarters of collected phishing samples request the introduction of credentials, we decided to crawl legitimate login websites to match the phishing standpoint. The developed approach is independent of third party services and the method relies on a new set of features used for the very first time in this problem, some of them extracted from the web technologies used by the on each specific website. Experimental results show that phishing websites can be detected with 97.95% accuracy using a LightGBM classifier and the complete set of the 54 features selected, when it was evaluated on PILWD dataset.SIINCIBEUniversidad de Leó
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P = 0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P = 0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P = 0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P = 0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P = 0.31). Conclusions: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.
Multi-interface network framework for UAV management and data communications
Recent efforts to manage Unmanned Aerial Vehicle (UAV) operations in European civilian environments have
resulted in the development of U-space, the European Union’s
UAS Traffic Management (UTM) concept of operations. This
paper presents the primary purposes of the H2020 Labyrinth
project (mainly focusing on the communications architecture),
which has as its main challenge to create and validate UAV
applications through the research and development of pathplanning algorithms and new UTM services. In addition, this
article performs a preliminary validation of a communications
prototype (including three communication alternatives) with real
equipment of the National Institute of Aerospace Technology
(INTA) of the Spanish Ministry of Defense. The presented results
show the functionality of the prototypes and serve as a starting
point to develop the requirements defined in the communications
architecture
Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Long-Term Registry.
AIMS: To evaluate how recommendations of European guidelines regarding pharmacological and non-pharmacological treatments for heart failure (HF) are adopted in clinical practice. METHODS AND RESULTS: The ESC-HF Long-Term Registry is a prospective, observational study conducted in 211 Cardiology Centres of 21 European and Mediterranean countries, members of the European Society of Cardiology (ESC). From May 2011 to April 2013, a total of 12 440 patients were enrolled, 40.5% with acute HF and 59.5% with chronic HF. Intravenous treatments for acute HF were heterogeneously administered, irrespective of guideline recommendations. In chronic HF, with reduced EF, renin-angiotensin system (RAS) blockers, beta-blockers, and mineralocorticoid antagonists (MRAs) were used in 92.2, 92.7, and 67.0% of patients, respectively. When reasons for non-adherence were considered, the real rate of undertreatment accounted for 3.2, 2.3, and 5.4% of the cases, respectively. About 30% of patients received the target dosage of these drugs, but a documented reason for not achieving the target dosage was reported in almost two-thirds of them. The more relevant reasons for non-implantation of a device, when clinically indicated, were related to doctor uncertainties on the indication, patient refusal, or logistical/cost issues. CONCLUSION: This pan-European registry shows that, while in patients with acute HF, a large heterogeneity of treatments exists, drug treatment of chronic HF can be considered largely adherent to recommendations of current guidelines, when the reasons for non-adherence are taken into account. Observations regarding the real possibility to adhere fully to current guidelines in daily clinical practice should be seriously considered when clinical practice guidelines have to be written